Companies exploring the use of hybrid or decentralized trials during this new era of drug development are encouraged to join this webinar for an interactive panel session featuring leaders from across the industry to learn from their direct experience.
During this live stream event, panelists will explore ways in which hybrid and decentralized trials have altered traditional clinical pathways and the new landscape that sponsors, sites and patients must navigate as a result of the COVID-19 pandemic. The panelists will also highlight the challenges and opportunities with transitioning to a hybrid or decentralized trial strategy and what they would recommend for those planning to do the same. Topics will include, but are not limited to data integrity, key stakeholders, trial design, operational considerations, essential infrastructure and insights into both the role and value these types of trials will have in the future.
Register today for this informative panel discussion to increase understanding of hybrid and decentralized trials as well as their impact to clinical research. When registering, please submit any questions or topics for the panel to discuss.
Niklas Morton, Senior Vice President, Digital Services, PPD
Niklas Morton serves as senior vice president of PPD’s digital services. In this role, he oversees the operations and delivery of digitally enabled and decentralized/virtual studies, along with PPD’s robotic automation capabilities. Since joining PPD in 1998 as a biostatistics manager, Morton has advanced through various roles of increasing leadership and responsibility within the company. He spent nearly five years in PPD’s project management department, where he had section-head responsibility for PPD’s Europe, Middle East and Africa (EMEA) hematology/oncology group.Message Presenter
Brittany Erana, Vice President, PPD Digital
Brittany Erana, M.P.M., is vice president and head of operations for PPD’s digital services. In this role, she’s responsible for setting the vision and designing the operational infrastructure and capabilities necessary to successfully deliver decentralized and digitally enabled clinical trials while upholding quality. Erana brings more than 15 years of broad industry experience in global research operations and strategy, digital implementation project and program delivery. She holds a Bachelor of Arts in psychology from East Carolina University, a master’s degree in project management from Western Carolina University and a certificate in international business from University College Dublin Smurfit Business School.Message Presenter
Who Should Attend?
- Clinical Research
- Clinical Operations
- Regulatory Affairs
- Clinical Affairs
- Outsourcing/Procurement Personnel
What You Will Learn
- Recommended strategies to digitally-enable research
- Critical design and operational considerations
- Challenges and opportunities created when pivoting to a hybrid or decentralized trial
- Predictions for the future use and impact of hybrid and decentralized trials
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 24,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health.